Business Wire

MD-CPSI

31.3.2020 21:17:07 CEST | Business Wire | Press release

Share
Get Real Health® Launches International Turnkey Telehealth Solution to Help Providers Address the COVID-19 Crisis While Enabling Virtual Connections for Other Patients in Need

Get Real Health®, a wholly owned subsidiary of healthcare solutions company CPSI (NASDAQ: CPSI), is launching a new solution called TalkWithYourDoc.com. The language-agnostic solution enables providers of all sizes around the globe to continue offering revenue-generating healthcare services while serving patients’ needs during the international COVID-19 pandemic.

TalkWithYourDoc.com supports multiple languages and right to left texts and allows patients to set preferred units and languages. Get Real Health brought the full breadth of its international experience to the development of this solution to make TalkWithYourDoc.com a truly global healthcare tool.

Get Real Health is a global leader in developing patient engagement platforms that transform the healthcare experience for patients and clinicians alike. As an international healthcare company, Get Real Health has deployed other solutions in England, The Netherlands, and Australia. The company also has pilots running in the Middle East and has had demonstration projects in Vietnam and Sweden.

TalkWithYourDoc.com, offered free of charge for the remainder of 2020, is an EHR-agnostic, HIPAA-compliant, secure solution that needs no EHR integration and enables quick provider/patient communication, engagement and data sharing without risk of disease transmission. The robust solution is designed to be user-friendly and operate without dedicated IT resources. A healthcare system, hospital or medical practice can have the solution up and running in hours, not days.

“TalkWithYourDoc.com enables clinicians anywhere in the world to see their patients like they’ve never seen them before,” said Robin Wiener, president of Get Real Health. “This is a secure monitoring tool that can aid a provider in diagnosing a patient. It also connects to patients’ medical devices for a 360-degree view of their conditions.”

This solution includes separate portals for both patients and their providers:

  • TalkWithYourDoc.com, also available as an Apple or Android App, allows the patient to fill out a COVID-19 screening survey, complete an initial questionnaire, and provide information about his or her underlying conditions and device readings (such as blood sugar). The patient portal also provides a suite of tools, including health journals, integration with home health devices, and a list of tasks that the provider would like the patient to complete.
  • The clinical portal enables the review of a patient’s health profile in preparation for the virtual appointment. It also provides alerts and updates to the clinician following the appointment.
  • The initial release can collect five key sets of information provided by the patient that can be used to effectively diagnose and treat the patient remotely. The five data sets include: current medications, chronic conditions, notable procedures the patient has undergone, allergies and a symptom tracker.

“TalkWithYourDoc.com not only helps clinicians respond faster and more efficiently to today’s often-overwhelming COVID-19 workload, but also helps support ongoing health and wellness,” said Wiener. “This is about much more than just talking with patients remotely. This innovative solution is keeping healthcare services flowing in a way that truly delivers excellent medical care, while maintaining vital revenue streams that healthcare organizations need to survive during this difficult time and beyond.”

About Get Real Health

Get Real Health, the newest member of the CPSI family of companies, combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools that they need to work together, we help our customers meet their ever-changing patient engagement needs. Our suite of products helps deliver value-based care, improve outcomes, activate patients, and increase patient loyalty and satisfaction, all while meeting regulatory requirements. Visit: www.getrealhealth.com .

About CPSI

CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and post-acute care facilities. Founded in 1979, CPSI is the parent of four companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC and iNetXperts, Corp. d/b/a Get Real Health. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting and managed IT services, along with its complete RCM solution for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. For more information, visit www.cpsi.com .

For more information about this solution, visit www.TalkWithYourDoc.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye